Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia.

ABSTRACT:

Background

The presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort.

Methods

A total of 780 patients with AML in first complete remission, with either intermediate- or adverse-risk cytogenetics, whose TP53 mutation status was reported, were included in this study from the European Society for Blood and Marrow Transplantation.

Results

Two-year overall survival (OS) was impaired in patients (n = 179) with evidence of a TP53 mutation at diagnosis (35.1%; 95% confidence interval [CI], 26.7-43.7) as compared to the cohort without (n = 

SUBMITTER: Loke J 

PROVIDER: S-EPMC9545190 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature